AstraZeneca (AZN) has cancelled a plan to invest 450 million pounds ($558.3 million) in a UK vaccine manufacturing plant in Liverpool.
Reduced UK government support is the main reason for withdrawing from the Speke facility development, the company said.
"Several factors have influenced this decision, including the timing and reduction of the final offer compared to the previous government's proposal," a company spokesperson said.
Despite the change in plans, the plant in Liverpool will continue to produce the company's flu vaccine, AstraZeneca said.
Price: 70.92, Change: -0.32, Percent Change: -0.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.